Emblica officinalis effect on endothelial dysfunction and biomarkers in metabolic syndrome subjects.
Not Applicable
Completed
- Conditions
- Health Condition 1: null- Metabolic syndrome
- Registration Number
- CTRI/2017/09/009606
- Lead Sponsor
- CGayatri Devi
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Not specified
- Target Recruitment
- 59
Inclusion Criteria
Patients were of either gender, aged 30-68 years, having endothelial dysfunction defined as <= 6% change in reflection index (RI) on post salbutamol challenge test and having metabolic syndrome.
Exclusion Criteria
Patients with severe uncontrolled hypertension, uncontrolled hyperglycemia, impaired hepatic or renal function, cardiac arrhythmia, history of smoking, chronic alcoholism, malignancy or stroke, any other serious disease requiring active treatment and treatment with any other herbal supplements
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method change in endothelial dysfunction as assessed by more than 6% change in reflection indexTimepoint: change in endothelial dysfunction as assessed by more than 6% change in reflection index after 12 weeks of treatment
- Secondary Outcome Measures
Name Time Method change in oxidative stress markers, serum levels of NO, GSH, MDA and hsCRP.safety and tolerability assessment of the test medicationsTimepoint: 12 weeks of treatment